Evidence map›Paper›PMID 39659642›Full record

ArticleJAC-antimicrobial resistance2024

Evaluating the effects of ivacaftor exposure on

Gretchen E Bollar, Kendall M Shaffer, Johnathan D Keith, Ashley M Oden, Alexander E Dowell, Kevin J Ryan, Edward P Acosta, Jennifer S Guimbellot, Megan R Kiedrowski, Susan E Birket

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Microbial and host innate immune factors affecting the persistence ofFrontiers in cellular and infection microbiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gretchen E BollarDepartment of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID https://orcid.org/0000-0002-6242-5317
Kendall M ShafferDepartment of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Johnathan D KeithGregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Ashley M OdenDepartment of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Alexander E DowellDepartment of Pharmacology and Toxicology, Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, AL, USA.
Kevin J RyanDepartment of Pharmacology and Toxicology, Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, AL, USA.
Edward P AcostaDepartment of Pharmacology and Toxicology, Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, AL, USA.
Jennifer S GuimbellotGregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Megan R KiedrowskiDepartment of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Susan E BirketDepartment of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID https://orcid.org/0000-0002-6353-6596

Funding

UAB CF Research and Translation Core CenterP30DK072482 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Susan Elizabeth Birket · 2007 to 2026
$23.0M
The Role of Airway Mucus in Infection and InflammationR01HL153079 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BIRKET, SUSAN ELIZABETH · 2021 to 2025
$2.2M
The Mechanisms Underlying Abnormal Mucus and its Clearance in the Cystic Fibrosis RatK08HL131867 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BIRKET, SUSAN ELIZABETH · 2017 to 2021
$637k
NHLBI NIH HHS K08 HL131867NHLBI NIH HHS R01 HL153079NIDDK NIH HHS P30 DK072482
6 · The paper itself

Abstract

Background: Ivacaftor exhibits anti-staphylococcal properties but does not clear Methods: Humanized G551D-CFTR (hG551D) rats were treated with ivacaftor for 7 days. Concentrations in the plasma, epithelial lining fluid and lung tissue lysate were measured using LC-MS/MS. Survival of Results: Ivacaftor plasma concentrations of treated hG551D rats reached 3.488 ± 1.118 µM, with more variable concentrations in the epithelial lining fluid and lung tissue lysate. During Conclusions: Treatment with ivacaftor did not alter

Identifiers

PMID39659642
PMCPMC11630538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.